➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Colorcon
Baxter
Johnson and Johnson
Moodys

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ISTRADEFYLLINE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Istradefylline

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00199355 ↗ A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa Completed Kyowa Hakko Kirin Company, Limited Phase 2 2005-04-01 To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
NCT00199368 ↗ An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 Completed Kyowa Hakko Kirin UK, Ltd. Phase 3 2004-10-01 This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
NCT00199368 ↗ An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 Completed Kyowa Kirin Pharmaceutical Development, Inc. Phase 3 2004-10-01 This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
NCT00199381 ↗ An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001 Terminated Kyowa Kirin Pharmaceutical Development, Inc. Phase 3 2005-10-01 This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
NCT00199394 ↗ A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease Completed Kyowa Hakko Kirin UK, Ltd. Phase 3 2004-11-01 The purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline (KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with advanced Parkinson's disease treated with levodopa.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Istradefylline

Condition Name

Condition Name for Istradefylline
Intervention Trials
Parkinson's Disease 16
Idiopathic Parkinson's Disease 2
Movement Disorder Syndrome 1
Hepatic Impairment 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Istradefylline
Intervention Trials
Parkinson Disease 18
Psychomotor Agitation 1
Parasomnias 1
Substance-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Istradefylline

Trials by Country

Trials by Country for Istradefylline
Location Trials
United States 51
Canada 6
Japan 5
Germany 2
Poland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Istradefylline
Location Trials
New Jersey 10
Florida 3
Arizona 3
North Carolina 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Istradefylline

Clinical Trial Phase

Clinical Trial Phase for Istradefylline
Clinical Trial Phase Trials
Phase 3 10
Phase 2/Phase 3 1
Phase 2 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Istradefylline
Clinical Trial Phase Trials
Completed 19
Terminated 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Istradefylline

Sponsor Name

Sponsor Name for Istradefylline
Sponsor Trials
Kyowa Kirin Pharmaceutical Development, Inc. 9
Kyowa Hakko Kirin Company, Limited 6
Kyowa Hakko Kirin Pharma, Inc. 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Istradefylline
Sponsor Trials
Industry 18
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Colorcon
Harvard Business School
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.